Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance.

Anti-Bacterial Agents / pharmacology Drug Design / methods Drug Resistance, Multiple / drug effects Humans Methicillin-Resistant Staphylococcus aureus / drug effects Nanoparticle Drug Delivery System / pharmacology Staphylococcal Infections / drug therapy

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
01 2021
Historique:
received: 28 07 2020
revised: 15 09 2020
accepted: 14 10 2020
pubmed: 23 10 2020
medline: 18 12 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Methicillin-resistant Staphylococcus aureus (MRSA) causes serious infections in both community and hospital settings, with high mortality rates. Treatment of MRSA infections is challenging because of the rapidly evolving resistance mechanisms combined with the protective biofilms of S. aureus. Together, these characteristic resistance mechanisms continue to render conventional treatment modalities ineffective. The use of nanoformulations with unique modes of transport across bacterial membranes could be a useful strategy for disease-specific delivery. In this review, we summarize treatment approaches for MRSA, including novel techniques in nanoparticulate designing for better therapeutic outcomes; and facilitate an understanding that nanoparticulate delivery systems could be a robust approach in the successful treatment of MRSA.

Identifiants

DOI: 10.1016/j.drudis.2020.10.011 PMID: 33091564 PMC: PMC7855522
pubmed: 33091564
pii: S1359-6446(20)30428-1
doi: 10.1016/j.drudis.2020.10.011
pmc: PMC7855522
mid: NIHMS1639011
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Nanoparticle Drug Delivery System 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-43

Subventions

Organisme : NIAID NIH HHS
ID : R56 AI151033
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Mol Interv. 2003 Mar;3(2):90-105, 51
pubmed: 14993430
Int J Antimicrob Agents. 2011 Feb;37(2):140-4
pubmed: 21130608
Clin Infect Dis. 2007 Sep 15;45 Suppl 3:S184-90
pubmed: 17712745
J Biomater Appl. 2011 Jan;25(5):387-400
pubmed: 20008087
J Microbiol Immunol Infect. 2013 Apr;46(2):89-95
pubmed: 22572005
Int J Nanomedicine. 2015 Jul 07;10:4351-66
pubmed: 26185439
J Control Release. 2008 Feb 11;125(3):210-27
pubmed: 18077047
J Appl Microbiol. 2002;92 Suppl:46S-54S
pubmed: 12000612
Lancet. 2001 Jul 14;358(9276):135-8
pubmed: 11463434
Nanomedicine. 2012 Jan;8(1):37-45
pubmed: 21703988
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15
pubmed: 23892192
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
Front Microbiol. 2018 Jun 26;9:1396
pubmed: 29997606
Clin Infect Dis. 2013 Jun;56(12):1685-94
pubmed: 23599308
Materials (Basel). 2018 Feb 23;11(2):
pubmed: 29473883
Infect Genet Evol. 2008 Dec;8(6):747-63
pubmed: 18718557
Ann Clin Microbiol Antimicrob. 2005 Jan 07;4:2
pubmed: 15638934
Nat Rev Drug Discov. 2007 Jan;6(1):29-40
pubmed: 17159923
Nanotechnology. 2005 Oct;16(10):2346-53
pubmed: 20818017
Clin Infect Dis. 2016 Jan 15;62(2):173-180
pubmed: 26349552
Antimicrob Agents Chemother. 2014 May;58(5):2989-92
pubmed: 24614378
Nat Commun. 2018 May 17;9(1):1969
pubmed: 29773788
Anaerobe. 2012 Apr;18(2):249-53
pubmed: 22155131
ACS Nano. 2012 Sep 25;6(9):7692-702
pubmed: 22870984
J Leukoc Biol. 2002 Sep;72(3):417-28
pubmed: 12223508
AAPS PharmSciTech. 2014 Dec;15(6):1527-34
pubmed: 25047256
Antimicrob Agents Chemother. 2011 May;55(5):2495-6; author reply 296-7
pubmed: 21527800
PLoS One. 2009 Nov 12;4(11):e7804
pubmed: 19915659
JAMA Intern Med. 2014 Dec;174(12):1920-1
pubmed: 25285726
J Antibiot (Tokyo). 2017 Dec;70(12):1087-1096
pubmed: 29089600
PLoS One. 2013 Apr 24;8(4):e62117
pubmed: 23637976
J Control Release. 2017 Nov 28;266:17-26
pubmed: 28911805
Nanoscale. 2013 Sep 21;5(18):8340-50
pubmed: 23893008
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Nat Rev Genet. 2010 Mar;11(3):181-90
pubmed: 20125085
Antimicrob Agents Chemother. 2013 Jun;57(6):2726-37
pubmed: 23571532
Part Fibre Toxicol. 2017 Aug 1;14(1):28
pubmed: 28764715
Biomed Res Int. 2018 Dec 27;2018:4657396
pubmed: 30687745
Antimicrob Agents Chemother. 2013 Nov;57(11):5717-20
pubmed: 23959320
Photodiagnosis Photodyn Ther. 2004 Dec;1(4):279-93
pubmed: 25048432
J Antimicrob Chemother. 2014 Feb;69(2):309-22
pubmed: 24072167
JAMA. 2020 Feb 11;323(6):527-537
pubmed: 32044943
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
J Am Chem Soc. 2011 Mar 23;133(11):4132-9
pubmed: 21344925
J Pediatr Pharmacol Ther. 2005 Jul;10(3):174-82
pubmed: 23118636
Biointerphases. 2007 Dec;2(4):MR17-71
pubmed: 20419892
J Antimicrob Chemother. 2010 Oct;65(10):2183-7
pubmed: 20729545
Nat Rev Microbiol. 2004 Feb;2(2):95-108
pubmed: 15040259
J Control Release. 2014 Aug 10;187:101-17
pubmed: 24878179
Int J Pharm. 2006 Jul 24;317(2):127-35
pubmed: 16624509
J Antimicrob Chemother. 2012 Sep;67(9):2191-4
pubmed: 22661572
Antimicrob Agents Chemother. 2009 Sep;53(9):3880-6
pubmed: 19564363
Antimicrob Agents Chemother. 2005 Jul;49(7):3025-7
pubmed: 15980391
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S47-S53
pubmed: 30895214
Infection. 1994 Sep-Oct;22(5):338-42
pubmed: 7843812
Nat Rev Microbiol. 2009 Sep;7(9):629-41
pubmed: 19680247
Colloids Surf B Biointerfaces. 2010 Sep 1;79(2):488-93
pubmed: 20627485
J Pharm Sci. 2008 Dec;97(12):5421-33
pubmed: 18393290
J Control Release. 2011 Dec 10;156(2):128-45
pubmed: 21763369
FASEB J. 2014 Dec;28(12):5071-82
pubmed: 25122556
Sci Rep. 2016 Mar 04;6:22595
pubmed: 26940762
Nanoscale. 2018 Mar 8;10(10):4927-4939
pubmed: 29480295
J Pharm Pharmacol. 2011 Jan;63(1):73-9
pubmed: 21155818
Nat Rev Microbiol. 2016 Aug 11;14(9):563-75
pubmed: 27510863
PLoS One. 2019 Sep 3;14(9):e0220684
pubmed: 31479462
ACS Nano. 2017 May 23;11(5):4428-4438
pubmed: 28350437
AIMS Microbiol. 2018 Jun 26;4(3):482-501
pubmed: 31294229
J Immunol. 2013 Mar 1;190(5):2159-68
pubmed: 23365077
Braz J Infect Dis. 2019 May - Jun;23(3):191-196
pubmed: 31207214
J Biomed Mater Res B Appl Biomater. 2012 Oct;100(7):1803-11
pubmed: 22807376
Infect Chemother. 2016 Dec;48(4):267-273
pubmed: 28032484
Front Microbiol. 2018 Mar 27;9:572
pubmed: 29636741
J Hosp Infect. 2004 Mar;56(3):208-14
pubmed: 15003669
J Nanosci Nanotechnol. 2014 Jul;14(7):4745-56
pubmed: 24757944
Antimicrob Resist Infect Control. 2017 Mar 28;6:32
pubmed: 28360994
Methods Mol Biol. 2014;1085:333-45
pubmed: 24085704
Appl Environ Microbiol. 2012 Apr;78(8):2768-74
pubmed: 22286985
Infect Dis Ther. 2014 Dec 18;:
pubmed: 25519162
Antimicrob Agents Chemother. 2014;58(1):102-9
pubmed: 24145519
World J Microbiol Biotechnol. 2012 Apr;28(4):1605-13
pubmed: 22805942
Curr Pharm Des. 2015;21(16):2089-100
pubmed: 25760334
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Pathog Immun. 2018 Feb 22;3(1):19-43
pubmed: 30993248
Int J Pharm. 2012 Oct 15;436(1-2):659-76
pubmed: 22841851
Medchemcomm. 2019 Mar 14;10(8):1231-1241
pubmed: 31534648
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9
pubmed: 16323118
J Neuroimmune Pharmacol. 2006 Sep;1(3):340-50
pubmed: 18040810
Cell. 2007 Mar 23;128(6):1037-50
pubmed: 17382878
Sci Rep. 2019 Jan 15;9(1):129
pubmed: 30644425
Nat Rev Drug Discov. 2003 Feb;2(2):114-22
pubmed: 12563302
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32094136
Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S678-83
pubmed: 26567287
Pathog Dis. 2016 Jun;74(4):ftw019
pubmed: 27036412
Int J Antimicrob Agents. 2008 Apr;31(4):321-8
pubmed: 18201873
Rev Soc Bras Med Trop. 2012 Jul-Aug;45(4):471-4
pubmed: 22930045
Antimicrob Agents Chemother. 2009 Aug;53(8):3505-7
pubmed: 19451285
Inflamm Res. 2012 Mar;61(3):207-15
pubmed: 22159524
Nanomedicine. 2007 Jun;3(2):161-7
pubmed: 17468055
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3976-9
pubmed: 27090173
Nat Rev Microbiol. 2020 May;18(5):275-285
pubmed: 31745331
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4983-90
pubmed: 27297479
Curr Infect Dis Rep. 2017 Nov 3;19(12):48
pubmed: 29101576
Curr Neuropharmacol. 2013 Mar;11(2):197-208
pubmed: 23997754
N Engl J Med. 1989 May 4;320(18):1188-96
pubmed: 2651925
Chemotherapy. 2006;52(4):178-84
pubmed: 16691027
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5804-16
pubmed: 20484584
Bioconjug Chem. 2012 Feb 15;23(2):164-73
pubmed: 22236254
PLoS One. 2017 May 9;12(5):e0176988
pubmed: 28486482
Am J Infect Control. 2008 Dec;36(10):S175.e9-11
pubmed: 19084156
Pathog Dis. 2016 Jul;74(5):
pubmed: 27154750

Auteurs

Kushal Vanamala (K)

Use-Inspired Biomaterials and Integrated Nano Delivery Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

Katyayani Tatiparti (K)

Use-Inspired Biomaterials and Integrated Nano Delivery Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

Ketki Bhise (K)

Use-Inspired Biomaterials and Integrated Nano Delivery Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

Samaresh Sau (S)

Use-Inspired Biomaterials and Integrated Nano Delivery Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

Marc H Scheetz (MH)

Departments of Pharmacy Practice and Pharmacology, Midwestern University Chicago College of Pharmacy and Graduate Studies, Pharmacometric Center of Excellence, Chicago, IL, USA.

Michael J Rybak (MJ)

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA; Division of Infectious Diseases, Department of Medicine, School of Medicine, Wayne State University, Detroit, MI, USA.

David Andes (D)

Division of Infectious Disease, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.

Arun K Iyer (AK)

Use-Inspired Biomaterials and Integrated Nano Delivery Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA; Molecular Imaging Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: arun.iyer@wayne.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Novel approaches for the treatment of...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Conception de médicament › Novel approaches for the treatment of...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Novel approaches for the treatment of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel approaches for the treatment of...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus résistant à la méticilline › Novel approaches for the treatment of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Système d'administration de médicaments à base de nanoparticules › Novel approaches for the treatment of...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à staphylocoques › Novel approaches for the treatment of...